Hostname: page-component-76d6cb85b7-rxvq6 Total loading time: 0 Render date: 2026-07-16T14:32:45.404Z Has data issue: false hasContentIssue false
  • English
  • Français

EVIDENCE REQUIRED BY HEALTH TECHNOLOGY ASSESSMENT AND REIMBURSEMENT BODIES EVALUATING DIAGNOSTIC OR PROGNOSTIC ALGORITHMS THAT INCLUDE OMICS DATA – ERRATUM

Published online by Cambridge University Press:  23 October 2018

Alexandre Barna ,
Teresita Cruz-Sanchez ,
Karen Berg Brigham ,
Cong-Tri Thuong ,
Finn Boerlum Kristensen  and
Isabelle Durand-Zaleski
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Keywords

BiomarkersAssessment and regulationReimbursement policyPersonalized medicine

Information

Type
Erratum
Information
International Journal of Technology Assessment in Health Care , Volume 34 , Issue 5 , 2018 , pp. 535
Copyright
Copyright © Cambridge University Press 2018 

Due to an error introduced during copyediting, the title of the publication by Barna et al. (2018) contained a typo. The title has since been corrected. The publisher apologizes for this error.

References

REFERENCE

1.Barna, A, et al. Evidence required by health technology assessment and reimbursement bodies evaluating diagnostic or prognostic algorithms that include omics data. International Journal of Technology Assessment in Health Care. 2018;34:368–377 doi: 10.1017/S026646231800048X.Google Scholar